Tag: OSE

A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the US NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics ...

At American Association for Cancer Research Annual (AACR) Meeting 2022New Orleans, April 8 – 13 NANTES, France, April 04, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) ...

Issued by the United States Patent and Trademark Office A New Protection Covering OSE-279 Until 2039 NANTES, France, March 21, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: ...

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.CoVepiT, based on 13 peptides, elicits durable T-cell immunity against a ...

NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the ...

Based on the global license agreement signed in April 2021, this first milestone triggers a €5 million payment from Veloxis Pharmaceuticals, Inc. to OSE Immunotherapeutics. NANTES, France, Jan. 31, 2022 ...

Issued by the Japanese Patent OfficeA New Protection Covering Tedopi® Until 2037 NANTES, France, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that ...

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer. Dominique Costantini, current Chairwoman ...

New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy volunteers vaccinated.Promising preclinical efficacy signals guide development in immunocompromised patients ...

NANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on Tedopi® (neoepitope-based ...